Gladstone Institutional Advisory’s Journey Medical DERM Stock Holding History

Gladstone Institutional Advisory’s Portfolio DERM Stock Details DERM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$142K	Sell	20,000 -6,571	-25%	-$37.5K	﹤0.01%	872
2026 Q1	$125K	Sell	26,571 -2,500	-9%	-$19.4K	﹤0.01%	814
2025 Q4	$224K	Buy	29,071 +500	+2%	+$3.92K	0.01%	721
2025 Q3	$203K	Sell	28,571 -4,283	-13%	-$31.1K	0.01%	754
2025 Q2	$236K	Sell	32,854 -4,000	-11%	-$27.6K	0.01%	665
2025 Q1	$217K	Buy	36,854 +6,873	+23%	+$33.8K	0.01%	671
2024 Q4	$117K	Sell	29,981 -3,500	-10%	-$19.1K	0.01%	682
2024 Q3	$189K	Hold	33,481	–	–	0.01%	662
2024 Q2	$189K	Buy	+33,481	New	+$138K	0.01%	629

Other funds holding DERM

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

PAIM

Punch & Associates Investment Management Edina, Minnesota $2.02B AUM 40.6% 1-Year Est. Return

PFCS

Pale Fire Capital SE Prague, Czech Republic $1.41B AUM 25.22% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

Summit Financial Parsippany, New Jersey $9.12B AUM 27.44% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Diametric Capital Boston, Massachusetts $948M AUM 47.49% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Gladstone Institutional Advisory's DERM Position: Q2 2026 in Review

Gladstone Institutional Advisory reduced its Journey Medical (DERM) stake by 25% in Q2 2026, selling an estimated $37.5K and leaving 20,000 shares worth $142K. The position accounts for ﹤0.01% of the portfolio, ranked #872.

Gladstone Institutional Advisory first reported a position in DERM in Q2 2024 and has held it in 9 quarters since. The position peaked at $236K in Q2 2025. 71 funds tracked by Wall St. Rank hold DERM as of Q2 2026.

Gladstone Institutional Advisory held 20,000 shares of Journey Medical worth $142K as of Q2 2026.
Gladstone Institutional Advisory sold 6,571 Journey Medical shares in Q2 2026, an estimated $37.5K.
Journey Medical made up ﹤0.01% of Gladstone Institutional Advisory's portfolio in Q2 2026, its #872 holding.
Gladstone Institutional Advisory first reported a position in Journey Medical in Q2 2024 and has held it in 9 quarters since.
Gladstone Institutional Advisory's Journey Medical position peaked at $236K in Q2 2025.
71 funds tracked by Wall St. Rank held Journey Medical as of Q2 2026.

Based on Gladstone Institutional Advisory's 13F filing for Q2 2026, filed 27 Jul 2026.